EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

CEL-SCI Corp (CVM) fair value: what the stock is really worth

As of Oct 12, 2026: fair value of CEL-SCI Corp $1.97, price $1.83, upside +7.5%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US1508377066

CS CEL-SCI Corp logo Thin data Oct 3, 2026

CEL-SCI Corp

CVM · US

Low PriorityFair Value upside is limited and quality is weak.

Fair value $1.97 · Fairly valued (+7.5%)
Quality 50/100
Moderate debt
Mixed vs. peers (4/9)
Weak Growth (revenue 5y −3.2 %/yr in USD)
Negative free cash flow
Narrow moat 5/100
Thin data
⚠ Dilution
Watch CEL-SCI Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$384.60 $0.9744 Fair Value $1.97 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range $0.9744 – $384.60 · fair‑value band $1.48 – $2.46 · the $1.83 price screens below the $1.97 fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow CEL-SCI in your weekly email

Every Wednesday you see whether CEL-SCI is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.

Show more

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Stock analysis

CEL-SCI Corp (CVM) currently trades at $1.83, while our model-based Fair Value estimate is $1.97, so the stock looks roughly fairly valued today (gap 7.0%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $5.39 per share, and 2 of the 3 models we run sit above the $1.83 price.

Bear case: the Multiples group reads lowest at $2.31, and 1 of the 3 models stay below the price. Evidence for this calculation is low.

Scenario range: $1.48 (bear) to $2.46 (bull), the price of $1.83 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

CEL-SCI Corp reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$25.4M in FY2025.

Key figures

Market cap $40.6M · EPS (TTM) $−1.69 · Return on equity −253% · Return on assets (EBIT) −81.6% · Revenue (TTM) $28.6K · Revenue growth (YoY) −62.7% · Free cash flow −$17.2B · Net cash $1.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 82% below its 52-week high and 88% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 7%, CVM screens richer than that median.

Fair Value models

Bear $1.48 Fair Value $1.97 Bull $2.46
Price $1.83 · Upside +7.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings $2.43 $5.39 $11.36 68
EV/EBITDA $1.74 $2.31 $2.89 67
NCAV (Graham) $0.0003 $0.0005 $0.0007 54
All 3 models by family
DCF Models
Owner Earnings $2.43 $5.39 $11.36 68
Multiples
EV/EBITDA $1.74 $2.31 $2.89 67
Asset-Based
NCAV (Graham) $0.0003 $0.0005 $0.0007 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

Of which business quality 54 · Market factors (momentum, volatility) 29

Profitability 0
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 100
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 45
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+20.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
Revenue growth 34 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,217.2% (2015) → −5,188.3% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CVM, get fair value alerts →

Compare CEL-SCI Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 593 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside +7.5% · Top 25%
Profitability
Return on assets −66.8% · Bottom 25%
Operating margin (TTM) 0.0% · Above median
Growth and dividend
Revenue growth −62.7% · Bottom 25%
Balance sheet
Debt / equity 0.84× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.55× · Pricier than median
PEG 1.12× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)43 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)58 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $746.54 $1,275 +71% vs CVM
Vertex Pharmaceuticals Incorporated VRTX $510.08 $561.09 +10% vs CVM
argenx SE ARGX $825.03 $907.53 +10% vs CVM
Samsung Biologics Co 207940 1,219,000 KRW 1,340,900 KRW +10% vs CVM
WuXi Biologics (Cayman) Inc 2269 HK$52.65 HK$57.92 +10% vs CVM
CSL Limited CSL A$181.46 A$179.90 −1% vs CVM
Alnylam Pharmaceuticals, Inc ALNY $232.68 $217.88 −6% vs CVM
BeOne Medicines AG ONC $354.47 $280.94 −21% vs CVM
Celltrion, Inc 068270 180,400 KRW 74,519 KRW −59% vs CVM
Royalty Pharma plc RPRX $56.93 $19.01 −67% vs CVM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CEL-SCI Corp · Fair Value
$1.97 +7%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "CEL-SCI Corp Fair Value". https://www.fairvalue-calculator.com/stock/CVM

Frequently asked questions

Is CEL-SCI Corp (CVM) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $1.97 versus a price of $1.83, about +7% upside (fairly valued).
What is the fair value of CVM?
Our model-based fair value for CEL-SCI Corp is $1.97 (as of Oct 3, 2026), built from audited fundamentals. The current price: $1.83.
What is the quality score of CVM?
CEL-SCI Corp has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CEL-SCI Corp (CVM)?
Our model-based price target is the fair value of $1.97 (as of Oct 3, 2026) from 3 valuation models. Cautious scenario $1.48, optimistic scenario $2.46. It is a calculation from audited fundamentals, not an analyst target.
What is the CEL-SCI Corp stock forecast for 2026?
Our models put fair value at $1.97, about +7% upside versus a price of $1.83 (fairly valued). Cautious scenario $1.48, optimistic scenario $2.46. The calculation is refreshed regularly with new filings.
What is the revenue of CEL-SCI Corp (CVM)?
CEL-SCI Corp reported trailing-twelve-month revenue of about $28.6K (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of CEL-SCI Corp (CVM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CEL-SCI Corp it is $1.97 per share (as of Oct 3, 2026), against a price of $1.83. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is CEL-SCI Corp stock overvalued or undervalued in 2026?
As of Oct 3, 2026, CVM trades below its calculated fair value: price $1.83, fair value $1.97, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CVM?
No. The price is what the market pays today ($1.83); the fair value is what the company's own numbers justify ($1.97). For CEL-SCI Corp the two are $0.1370 per share apart. That gap is exactly why we show both numbers side by side.
How much is CEL-SCI Corp worth?
The market values CEL-SCI Corp at about $40.6M (market capitalisation, as of Oct 3, 2026). Per share that is $1.83; our models calculate a fair value of $1.97 per share.
What do the bullish and bearish scenarios say about CVM?
Our models span a range for CEL-SCI Corp: cautious scenario $1.48, base $1.97, optimistic $2.46 per share (as of Oct 3, 2026, price $1.83). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of CVM?
The PEG ratio of CEL-SCI Corp is 1.12 (P/E divided by earnings growth, as of Oct 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of CEL-SCI Corp (CVM)?
Balance-sheet figures for CEL-SCI Corp (as of Oct 3, 2026): return on equity −252.5%, debt of 0.84 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is CVM from its 52-week high?
CEL-SCI Corp trades at $1.83, about 82% below its 52-week high of $10.11 and 88% above the low of $0.9744 (as of Oct 12, 2026). Distance from the high says nothing about value: that is what the fair value of $1.97 is for.
Which stocks are comparable to CEL-SCI Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CEL-SCI Corp stock attractive at the current price?
The data as of Oct 3, 2026: price $1.83, calculated fair value $1.97 (+7%), Quality Score 50/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CVM calculated?
We run CEL-SCI Corp through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.97, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.8 % above its aggregate fair value. CEL-SCI Corp currently trades 7 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CEL-SCI Corp (CVM)?
The closing price on Oct 12, 2026 was $1.83. Our model-based fair value is $1.97, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CEL-SCI Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of CEL-SCI Corp

How large is the market capitalisation of CEL-SCI Corp (CVM)?
The market capitalisation of CEL-SCI Corp is $40.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of CEL-SCI Corp (CVM)?
Earnings per share at CEL-SCI Corp are $−1.69. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CEL-SCI Corp (CVM)?
The return on equity (ROE) of CEL-SCI Corp is −253% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CEL-SCI Corp (CVM)?
On an EBIT basis the return on assets of CEL-SCI Corp is −81.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at CEL-SCI Corp (CVM)?
Revenue at CEL-SCI Corp is growing −62.7% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CEL-SCI Corp (CVM) generate?
The free cash flow of CEL-SCI Corp is −$17.2B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CEL-SCI Corp (CVM) hold?
CEL-SCI Corp holds more cash than debt, $1.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch CEL-SCI Corp in the live analysis

One click puts CEL-SCI Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.